Stock listing

Monopar Therapeutics Inc.

Selected listing: A40JML · LSX · EUR · DE

Monopar Therapeutics Inc. (LS Exchange: A40JML), Health Technology. Latest release Aug 19, 2026: Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice…

A40JML:LSXEURDEUpdated September 25, 2026

Ticker: LS Exchange: A40JML
Asset type: Stock
Sector: Health Technology
Industry: Biotechnology
Exchange: LS Exchange
Currency: EUR

Latest news from Monopar Therapeutics Inc.

Monopar Appoints Jeffrey D. Kent, M.D., as Executive Vice President, Head of Medical Affairs; Announces Two ALXN1840 Presentations at AASLD – The Liver Meeting® 2026

August 19, 2026

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 13, 2026

Monopar Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 12, 2026

Monopar Initiates Rolling NDA Submission for ALXN1840 in Wilson Disease

July 22, 2026

Monopar Advances Launch Readiness with Addition of Veteran Commercial Executive Nicole Sweeny to Board of Directors and Expansion of Commercial Leadership Team

July 20, 2026

All Monopar Therapeutics Inc. news →

Research Monopar Therapeutics Inc.

Monopar Therapeutics Inc. company profile

View the public company page for Monopar Therapeutics Inc. on 6ix.

Monopar Therapeutics Inc. news

Read company news and market updates connected to Monopar Therapeutics Inc..

Monopar Therapeutics Inc. investor events

Find investor webinars, events, and replay context for Monopar Therapeutics Inc..